This post-hoc analysis of a Phase 1/2 randomized, placebo-controlled trial evaluated the efficacy of systemic administration of bone marrow-derived allogeneic mesenchymal stromal cells (remestemcel-L) in COPD patients stratified by baseline C-reactive protein (CRP) levels. In patients with CRP ≥ 4 mg/L, remestemcel-L treatment led to significant improvements in forced expiratory
